Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma.-Reference-Cited by-同舟云学术

Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:e23568-e23568
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Chawla Sant P.¹,Sankhala Kamalesh Kumar¹,Ravicz Joshua¹,Kang Grace¹,Liu Seiya²,Stumpf Nathan¹,Leong Bryan¹,Kim Seth¹,Arasheben Susan¹,Tseng William W.³,Gordon Erlinda Maria¹

Affiliation:

1. Sarcoma Oncology Center, Santa Monica, CA;

2. Sarcoma Oncology Research Center, Santa Monica, CA;

3. The University of Texas MD Anderson Cancer Center, Houston, TX;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.36.15_suppl.e23568

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab/trabectedin;Reactions Weekly;2024-04-27

2. Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series;Case Reports in Oncology;2024-02-23

3. Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311);Frontiers in Oncology;2023-05-10

4. Current Landscape of Immunotherapy for Advanced Sarcoma;Cancers;2023-04-13

5. SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma;Cancers;2023-01-31